Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder
Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder
Objectives To use growth mixture modelling (GMM) to identify subgroups of children with attention deficit hyperactive disorder (ADHD) who have different pharmacodynamic profiles in response to extended release methylphenidate as assessed in a laboratory classroom setting.
Methods GMM analysis was performed on data from the COMACS study (Comparison of Methylphenidates in the Analog Classroom Setting): a large (n = 184) placebo-controlled cross-over study comparing three treatment conditions in the Laboratory School Protocol (with a 1.5-h cycle of attention and deportment assessments). Two orally administered, once-daily methylphenidate (MPH) bioequivalent formulations [Metadate CD™/Equasym™ XL (MCD-EQXL) and Concerta XL (CON)] were compared with placebo (PLA).
Results Three classes of children with distinct severity profiles in the PLA condition were identified. For both MCD-EQXL and CON, the more severe their PLA symptoms the better, the children’s response. However, the formulations produced different growth curves by class, with CON having essentially a flat profile for all three classes (i.e. no effect of PLA severity) and MCD-EQXL showing a marked decline in symptoms immediately post-dosing in the two most severe classes compared with the least severe. Comparison of daily doses matched for immediate-release (IR) components accounted for this difference.
Conclusion The results suggest considerable heterogeneity in the pharmacodynamics of MPH response by children with ADHD. When treatment response for near-equal, bioequivalent daily doses the two formulations was compared, marked differences were seen for children in the most severe classes with a strong curvilinear trajectory for MCD-EQXL related to the greater IR component.
pharmacodynamics, pharmacokinetics, attention deficit/hyperactivity disorder, stimulant medication, methylphenidate, COMACS, growth mixture models
245-254
Sonuga-Barke, E.J.S.
bc80bf95-6cf9-4c76-a09d-eaaf0b717635
Van Lier, P.
e851ebd9-2d46-4f0a-8679-cc065ddb65f0
Swanson, J.M.
745c2c76-3510-4542-850d-4d084f748b2c
Coghill, D.
a4b982d1-4788-41aa-90c5-b4a7f7dffad7
Wigal, S.
fca8cee6-bdcc-4b17-bdc0-f4e985d251c4
Vandenberghe, M.
6bebf94b-30a0-4963-9c21-adc9b02b9a5d
Hatch, S.
4b6224bb-6a4e-49b2-9703-0a84d5d12525
2008
Sonuga-Barke, E.J.S.
bc80bf95-6cf9-4c76-a09d-eaaf0b717635
Van Lier, P.
e851ebd9-2d46-4f0a-8679-cc065ddb65f0
Swanson, J.M.
745c2c76-3510-4542-850d-4d084f748b2c
Coghill, D.
a4b982d1-4788-41aa-90c5-b4a7f7dffad7
Wigal, S.
fca8cee6-bdcc-4b17-bdc0-f4e985d251c4
Vandenberghe, M.
6bebf94b-30a0-4963-9c21-adc9b02b9a5d
Hatch, S.
4b6224bb-6a4e-49b2-9703-0a84d5d12525
Sonuga-Barke, E.J.S., Van Lier, P., Swanson, J.M., Coghill, D., Wigal, S., Vandenberghe, M. and Hatch, S.
(2008)
Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder.
European Child & Adolescent Psychiatry, 17, .
(doi:10.1007/s00787-007-0667-3).
Abstract
Objectives To use growth mixture modelling (GMM) to identify subgroups of children with attention deficit hyperactive disorder (ADHD) who have different pharmacodynamic profiles in response to extended release methylphenidate as assessed in a laboratory classroom setting.
Methods GMM analysis was performed on data from the COMACS study (Comparison of Methylphenidates in the Analog Classroom Setting): a large (n = 184) placebo-controlled cross-over study comparing three treatment conditions in the Laboratory School Protocol (with a 1.5-h cycle of attention and deportment assessments). Two orally administered, once-daily methylphenidate (MPH) bioequivalent formulations [Metadate CD™/Equasym™ XL (MCD-EQXL) and Concerta XL (CON)] were compared with placebo (PLA).
Results Three classes of children with distinct severity profiles in the PLA condition were identified. For both MCD-EQXL and CON, the more severe their PLA symptoms the better, the children’s response. However, the formulations produced different growth curves by class, with CON having essentially a flat profile for all three classes (i.e. no effect of PLA severity) and MCD-EQXL showing a marked decline in symptoms immediately post-dosing in the two most severe classes compared with the least severe. Comparison of daily doses matched for immediate-release (IR) components accounted for this difference.
Conclusion The results suggest considerable heterogeneity in the pharmacodynamics of MPH response by children with ADHD. When treatment response for near-equal, bioequivalent daily doses the two formulations was compared, marked differences were seen for children in the most severe classes with a strong curvilinear trajectory for MCD-EQXL related to the greater IR component.
This record has no associated files available for download.
More information
Published date: 2008
Keywords:
pharmacodynamics, pharmacokinetics, attention deficit/hyperactivity disorder, stimulant medication, methylphenidate, COMACS, growth mixture models
Identifiers
Local EPrints ID: 50227
URI: http://eprints.soton.ac.uk/id/eprint/50227
ISSN: 1018-8827
PURE UUID: 18cbfb9a-e88f-4113-8e9d-88ab344528ce
Catalogue record
Date deposited: 01 Feb 2008
Last modified: 15 Mar 2024 10:04
Export record
Altmetrics
Contributors
Author:
E.J.S. Sonuga-Barke
Author:
P. Van Lier
Author:
J.M. Swanson
Author:
D. Coghill
Author:
S. Wigal
Author:
M. Vandenberghe
Author:
S. Hatch
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics